Fortress Biotech Inc (FBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.72+0.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Increase royalty revenue from ZYCUBO and UNLOXCYT: YoY rev +14.0% vs 61% target.
Fortress Biotech has FDA approval for ZYCUBO, a rare disease drug. Analysts expect revenue to grow about 61% next year. The company aims to increase royalty revenue from ZYCUBO and UNLOXCYT. Its stock trades cheaply with a PE of 0.94, well below peers.
The company has volatile management and fragile quality. Recent earnings were mixed with a miss and a beat. Litigation and capital allocation issues add risk. The stock price is down 70% from analyst targets.
The market prices in about 61% revenue growth next year. Our fair value is near $10, close to consensus estimates, reflecting this growth. We see risk in management execution and legal issues that may delay growth.
Breaks if: Loss or suspension of FDA approval for ZYCUBO
Achieve FDA approval for ZYCUBO for the treatment of Menkes disease in pediatric patients.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
FBIO represents a speculative growth investment, with a focus on advancing clinical programs and expanding market access. The current thesis state is weakened due to recent financial performance dropping within its industry.
The market seems to price FBIO as a cheap option compared to its peers, with a low expectations gap indicating that investors may not expect strong near-term performance. The valuation reflects a justified position, but with fragility stemming from weak execution quality.
Management is on track with increasing royalty revenue and expanding commercial access for dermatology products. However, recent financial performance has been weak, and the mixed results in clinical development may pose risks in the near term.
The thesis hinges on the company's ability to maintain guidance and avoid cuts, as well as the overall health of the job market impacting cyclical names. Additionally, positive earnings and guidance from sector leaders could provide momentum for FBIO.
The most important moves since the prior daily snapshot.
Signal changed from 'favorable' to 'mild_favorable'.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change indicates that the reason to own FBIO has weakened significantly. The market has not reacted strongly, with only a modest price movement compared to the S&P.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Major management turnover or governance issues arise
Breaks if: YoY revenue growth falls below 40% in FY27
Focus on growing royalty income from recently approved ZYCUBO and UNLOXCYT products and potential milestone payments across the portfolio.
Stated as a priority in 2 of last 2 quarters. Consolidated net revenue increased from $16.4 million in 2025-Q2 to $18.7 million in 2026-Q2. Fortress recognized $0.1 million in royalty income on UNLOXCYT and Cyprium recognized $0.2 million on ZYCUBO in 2026-Q2. The trajectory shows delivering growth in royalty revenue consistent with management's stated focus.
“Royalties generated from the launches of ZYCUBO and UNLOXCYT.”
“Looking ahead, we expect to generate increasing royalty revenue from ZYCUBO and UNLOXCYT.”
Over the next 1 to 3 years, FBIO's performance will depend on its execution and external market conditions. Not investment advice.